HLS Therapeutics Inc (HLS) - Total Liabilities
Based on the latest financial reports, HLS Therapeutics Inc (HLS) has total liabilities worth CA$78.49 Million CAD (≈ $56.78 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore HLS Therapeutics Inc (HLS) cash flow conversion to assess how effectively this company generates cash.
HLS Therapeutics Inc - Total Liabilities Trend (1996–2024)
This chart illustrates how HLS Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. Check HLS asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
HLS Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of HLS Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Geodrill Ltd
F:7GD
|
Germany | €49.18 Million |
|
AleAnna, Inc. Class A Common Stock
NASDAQ:ANNA
|
USA | $41.73 Million |
|
Clarus Corp
NASDAQ:CLAR
|
USA | $57.27 Million |
|
Scully Royalty Ltd
NYSE:SRL
|
USA | $124.67 Million |
|
Frequency Therapeutics Inc
NASDAQ:KRRO
|
USA | $62.52 Million |
|
Adda Corporation
TWO:3071
|
Taiwan | NT$1.95 Billion |
|
Ruentex Materials Co Ltd
TW:8463
|
Taiwan | NT$6.94 Billion |
|
EcoFirst Consolidated Bhd
KLSE:3557
|
Malaysia | RM463.23 Million |
Liability Composition Analysis (1996–2024)
This chart breaks down HLS Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see HLS Therapeutics Inc market cap and net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.17 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.27 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.56 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how HLS Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for HLS Therapeutics Inc (1996–2024)
The table below shows the annual total liabilities of HLS Therapeutics Inc from 1996 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CA$88.56 Million ≈ $64.07 Million |
-20.47% |
| 2023-12-31 | CA$111.36 Million ≈ $80.56 Million |
-4.27% |
| 2022-12-31 | CA$116.33 Million ≈ $84.15 Million |
+1.01% |
| 2021-12-31 | CA$115.17 Million ≈ $83.31 Million |
-14.47% |
| 2020-12-31 | CA$134.66 Million ≈ $97.41 Million |
-4.82% |
| 2019-12-31 | CA$141.47 Million ≈ $102.34 Million |
-4.37% |
| 2018-12-31 | CA$147.94 Million ≈ $107.01 Million |
-27.58% |
| 2017-12-31 | CA$204.26 Million ≈ $147.76 Million |
+36901.53% |
| 2016-12-31 | CA$552.04K ≈ $399.34K |
-3.52% |
| 2015-12-31 | CA$572.17K ≈ $413.90K |
-95.74% |
| 2014-12-31 | CA$13.42 Million ≈ $9.71 Million |
-6.10% |
| 2013-12-31 | CA$14.29 Million ≈ $10.34 Million |
+64.46% |
| 2012-12-31 | CA$8.69 Million ≈ $6.28 Million |
-35.40% |
| 2011-12-31 | CA$13.45 Million ≈ $9.73 Million |
+10.51% |
| 2010-12-31 | CA$12.17 Million ≈ $8.80 Million |
-30.62% |
| 2009-12-31 | CA$17.54 Million ≈ $12.69 Million |
+0.07% |
| 2008-12-31 | CA$17.53 Million ≈ $12.68 Million |
-37.18% |
| 2007-12-31 | CA$27.90 Million ≈ $20.18 Million |
+50.64% |
| 2006-12-31 | CA$18.52 Million ≈ $13.40 Million |
+30.65% |
| 2005-12-31 | CA$14.18 Million ≈ $10.25 Million |
+22.65% |
| 2004-12-31 | CA$11.56 Million ≈ $8.36 Million |
-22.00% |
| 2003-12-31 | CA$14.82 Million ≈ $10.72 Million |
+255.47% |
| 2002-12-31 | CA$4.17 Million ≈ $3.02 Million |
-29.57% |
| 2001-12-31 | CA$5.92 Million ≈ $4.28 Million |
-54.82% |
| 2000-12-31 | CA$13.10 Million ≈ $9.48 Million |
-43.87% |
| 1999-12-31 | CA$23.34 Million ≈ $16.88 Million |
+31.05% |
| 1998-12-31 | CA$17.81 Million ≈ $12.88 Million |
-25.92% |
| 1997-12-31 | CA$24.04 Million ≈ $17.39 Million |
+138.23% |
| 1996-12-31 | CA$10.09 Million ≈ $7.30 Million |
-- |
About HLS Therapeutics Inc
HLS Therapeutics Inc., a specialty pharmaceutical company, acquires and commercializes pharmaceutical products for the treatment of psychiatric disorders, central nervous system, and cardiovascular disease in Canada, the United States, and internationally. The company's lead products include Clozaril, an atypical antipsychotic for management of symptoms of treatment-resistant schizophrenia; and V… Read more